Measurable Data Token (MDT) news

BUZZ—U.S. Stock Market Update—SpaceX, Humana, Crescent Energy

Query string for tracking individual stock trends: STXBZ "Today's Outlook" newsletter: https://refini.tv/3LI4BU7 "Morning News Briefing": https://refini.tv/3dKUyB8 Reuters, October 9 – On Friday, U.S. stock indices are expected to open higher, boosted by falling oil prices as concerns over Middle East supply ease, although telecom stocks remain under pressure amid worries of increased industry-wide competition following SpaceX's spectrum acquisition. ** T-Mobile US Inc TMUS.O: In Discussion – European telecom stocks fell after SpaceX's spectrum deal nL6N45V0EH ** SpaceX SPCX.O: In Focus – Shares rose after reaching an agreement to acquire a nationwide low-band spectrum portfolio nL4N45V0KP ** Humana Inc HUM.N: In Focus – Shares rose on the back of an upgraded rating for its “Federal Medicare Advantage Plan” [nL4N45V0LU ** Definium Therapeutics Inc DFTX.O: Market Watch – Stock rose after JPMorgan rated its LSD-based therapies as “Overweight” nL4N45V0NH ** UnitedHealth Group Inc UNH.N: Market Update – TD Cowen lowered its price target ahead of UnitedHealth’s Q3 financials nL4N45V0OU ** Newmont Corporation NEM.N: ** Gold Fields Ltd GFI.N: ** Harmony Gold Mining Company HMY.N: ** AngloGold Ashanti AU.N: Market Update – Gold miner stocks rose modestly as gold prices moved up on weaker dollar nL4N45V0PG ** Delta Air Lines DAL.N: Market Flash – Shares dropped after sharply cutting its full-year profit guidance nL4N45V0RA ** Apple AAPL.O: In Focus – Shares fell on reports of iPhone production cuts nL4N45V0SB ** Crescent Energy CRGY.N: Market Update – Shares dropped after it raised $1 billion to acquire Devon Energy nL6N45V0J4 ** Medtronic MDT.N: ** Tandem Diabetes Care Inc TNDM.O: ** PROCEPT BioRobotics Corp PRCT.O: ** Insulet Corporation PODD.O: Market Update – Leerink says industry-wide growth concerns for med-tech may outweigh Q3 results nL4N45V0YE (For the convenience of non-English speakers, Reuters automates translation of its reports into several languages. Because automated translations may contain errors or fail to capture the intended context, Reuters does not guarantee the accuracy of these texts and provides them solely for reader convenience. Reuters assumes no liability for any damages or losses resulting from the use of automated translation features.)

BUZZ - Leerink says concerns over growth in the medical technology sector may overshadow third-quarter performance

October 9 – Leerink Partners stated that, ahead of the third-quarter earnings reports, it remains cautious on the medical technology sector and pointed out that the short-term market environment is “somewhat uncertain.” The firm noted increasing competition in some markets, including the cardiac devices and diabetes care sectors; uncertainty in surgical volumes amid rising costs; weak consumer confidence; and pressure on hospital budgets due to higher interest rates. “We believe that even if third-quarter results are positive, they may be overshadowed by ongoing market concerns about profitability and growth prospects for 2027 and beyond,” the broker said. The firm believes that positive factors for specific companies could help Medtronic (MDT.N) and Tandem Diabetes Care (TNDM.O) outperform the broader industry during these sector-wide headwinds. The broker said it remains most cautious on PROCEPT BioRobotics (PRCT.O) and Insulet (PODD.O), as a slowdown in adoption and intensifying competition may lead to lowered expectations for 2027. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translation may contain errors or fail to capture the required context, Reuters does not guarantee the accuracy of automated translation texts, and they are provided merely for readers’ convenience. Reuters accepts no liability for any damage or loss resulting from the use of automated translation features.)

The strongest growth outlook in over two years is approaching! US medical device stocks still need to endure another sluggish earnings season

The third-quarter profit growth of medical device companies is expected to be only 4.8%, but it is projected to accelerate to 13% in the first quarter of next year, marking the strongest performance in over two years. However, policy uncertainties and product recalls have dampened confidence, and the market is awaiting a recovery by 2027.

Revenue surges by 42% and returns to profitability! Artificial disc leader Centinel Spine races for US IPO as innovative medical devices face valuation test

Centinel Spine is a medical device company headquartered in West Chester, Pennsylvania, USA, specializing in Total Disc Replacement (TDR). Its core prodisc platform covers artificial cervical and lumbar discs, aiming to replace diseased discs while preserving the mobility of the treated segment and providing an alternative treatment option to spinal fusion surgery for eligible patients.

Medtronic sets final 4.5939 exchange ratio in MiniMed split-off offer

Medtronic set a final exchange ratio of 4.5939 MiniMed shares for each Medtronic ordinary share accepted in its MiniMed split-off. The ratio hit the offer’s upper limit, since the calculated exchange ratio based on reference prices would have been higher. Up to 225,361,295 MiniMed shares are available in the exchange offer; an oversubscription could add 27,452,053 more MiniMed shares. At the final ratio, Medtronic would take about 55,032,401 shares if it tenders its remaining MiniMed stake, or about 49,056,639 otherwise. The exchange offer and withdrawal rights are scheduled to expire at midnight New York time on Oct. 9, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610071731PR_NEWS_USPR_____CG66440) on October 07, 2026, and is solely responsible for the information contained therein.

Medtronic posts 24-month TITAN 2 data showing sustained nocturia reduction with Altaviva device

Medtronic disclosed new 24-month exploratory results from the TITAN 2 pivotal trial at the 47th AUGS Annual Scientific Meeting. The analysis showed durable reductions in nightly urination episodes, with sleep-related quality of life improving for many patients. The update supports the clinical profile of Altaviva, an implantable tibial neuromodulation device cleared in September 2025 for urge urinary incontinence. Medtronic also launched the ENDURANCE post-approval study, a five-year, real-world trial tracking 170 implanted patients across up to 30 US centers. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein.

Medtronic says FY26 Impact Report shows 68% cut in Scope 1 and 2 emissions intensity vs FY20 baseline

Medtronic released its fiscal 2026 Impact Report, citing more than 82 million patients served worldwide. R&D investment totaled $2.9 billion, supporting more than 315 product approvals in major markets, including FDA clearance of the Hugo surgical robot. Quality nonconformances fell 70% through expanded First Time Quality programs across manufacturing, distribution, and service operations. Scope 1 and 2 emissions intensity dropped 68% versus the fiscal 2020 baseline; renewable electricity sourcing rose to 65%. Supplier engagement on Scope 3 targets increased to about 18%; packaging materials fell by 230 tonnes. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein.

Northwest Bank provides $34.5 million loan for Luzern Associates' $47.75 million Cherry Hill industrial portfolio acquisition

Northwest Bancshares’ Northwest Bank provided USD 34.5 million financing for Luzern Associates’ USD 47.75 million Cherry Hill industrial portfolio acquisition. Deal covers a three-building campus in Danvers, Massachusetts totaling nearly 200,000 square feet. Medtronic occupies about 70% of the portfolio’s square footage; properties are fully occupied. Loan structured as commercial real estate financing; remaining purchase price funded with equity from a strategic investor. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Northwest Bancshares Inc. published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein.

Stryker Corp. Stock Rises 3.6%, Outperforms Market

This article was automatically generated by Dow Jones using technology from Automated Insights. Shares of Stryker Corp. advanced 3.6% to $285.22 on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.7% to 7,773.95 and the Dow Jones Industrial Average rising 0.2% to 51,267.90. This was the stock's second consecutive day of gains. Stryker Corp. closed 27.3% short of its 52-week high of $392.55, which the company reached on October 22nd. The stock demonstrated a mixed performance when compared to some of its peers, as Medtronic PLC rose 1.8% to $87.97, Intuitive Surgical Inc. rose 3.7% to $406.48, and Edwards Lifesciences Corp. rose 2.44% to $87.23. Trading volume totaled 3.3 million, compared to the 50-day average of 2.7 million. Data source: Dow Jones Market Data, FactSet (END) Dow Jones Newswires October 05, 2026 16:35 ET (20:35 GMT)

Zimmer Biomet Holdings Inc. Stock Advances 3.7%, Outperforms Peers

This article was automatically generated by Dow Jones using technology from Automated Insights. Shares of Zimmer Biomet Holdings Inc. rallied 3.7% to $91.57 on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.7% to 7,773.95 and the Dow Jones Industrial Average rising 0.2% to 51,267.90. This was the stock's second consecutive day of gains. Zimmer Biomet Holdings Inc. closed 14.3% below its 52-week high of $106.88, which the company reached on October 22nd. The stock outperformed some of its peers, as Johnson & Johnson fell 1.2% to $252.93, Medtronic PLC rose 1.8% to $87.97, and Stryker Corp. rose 3.55% to $285.22. Trading volume totaled 2.3 million, compared to the 50-day average of 2.2 million. Data source: Dow Jones Market Data, FactSet (END) Dow Jones Newswires October 05, 2026 16:35 ET (20:35 GMT)

Intuitive Surgical Inc. Stock Rallies 3.7%, Outperforms Peers

This article was automatically generated by Dow Jones using technology from Automated Insights. Shares of Intuitive Surgical Inc. rose 3.7% to $406.48 on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.7% to 7,773.95 and the Dow Jones Industrial Average rising 0.2% to 51,267.90. The stock's rise snapped a four-day losing streak. Intuitive Surgical Inc. closed 32.7% short of its 52-week high of $603.88, which the company reached on January 7th. The stock outperformed some of its peers, as Medtronic PLC rose 1.8% to $87.97, Stryker Corp. rose 3.6% to $285.22. Trading volume totaled 1.7 million, compared to the 50-day average of 2.6 million. Data source: Dow Jones Market Data, FactSet (END) Dow Jones Newswires October 05, 2026 16:35 ET (20:35 GMT)

Medtronic reports 88.1% ulcer healing rate at 24 months in VenaSeal venous leg ulcer study

Medtronic reported new 24-month results from its VenaSeal Spectrum Venous Leg Ulcer study, presented at the 2026 VEINS conference. Data showed the device supported durable ulcer healing, symptom relief, quality-of-life gains, sustained vein closure, low repeat-treatment needs. Management framed the evidence as strengthening physician confidence in VenaSeal for advanced chronic venous disease, including active ulcers. U.S. commercial and Medicare coverage expanded to 96% of insured lives, lowering reimbursement friction for broader adoption. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief on October 03, 2026, and is solely responsible for the information contained therein.

Danaher Corp. Stock Slides 4.4%, Underperforms Peers

Orchestra BioMed surpasses enrollment target in BACKBEAT pivotal trial of AVIM hypertension therapy

Medtronic Reveals Regulatory Milestones for Software Used With Cardiac Ablation Platforms

Medtronic wins FDA clearance for Affera Prism-2 cardiac mapping software

Nexalin names Abbott, Medtronic veteran Robert DiTota senior strategic advisor for global commercialization

nVent names Courtney Nelson Wills as general counsel, effective Oct. 12

Alphatec appoints Tommy Carls EVP, Data Intelligence and Strategy

Medtronic's Deal with Cornerstone Robotics to Complement Hugo Surgery System, Needham Says

Edwards Lifesciences Corp. Stock Advances 4.1%, Outperforms Peers

Medtronic Gets US FDA Clearance for LigaSure RAS Maryland Device on Hugo System

MiniMed Files S-4 as Medtronic Seeks to Exit Remaining Stake

Medtronic Intends to Exchange All Remaining Interest in MiniMed (Additional 27.5M Shrs), Without Extending Exchange Offer Period if Exchange Offer Is Oversubscribed

Medtronic Currently Owns About 89.86% of Total Outstanding Shrs of MiniMed Common Stk >MMED

Medtronic: Exchange Offer Is Expected to Be Generally Tax-Free to Co. and Participating Hldrs >MDT

Medtronic: Exchange Offer Will Permit Hldrs to Exchange Their Ordinary Shrs for Shrs of MiniMed Common Stk at 7% Discount >MDT

Medtronic Commenced Exchange Offer to Split Off at Least 80.1% of Shrs of MiniMed Group >MDT

Medtronic Launches Exchange Offer to Complete Separation of MiniMed Group, Inc.

Boston Scientific Corp. Stock Falls 4.1%, Underperforms Peers